Prior authorization / coverage review for listed CPT/HCPCS/J‑codes

Certain CPT, HCPCS and J‑codes listed as not covered for the indications in this bulletin may trigger claim denial or require coverage review; prior authorization may be required when these services are proposed. Examples include extracorporeal shock wave (0101T), plastic repair of introitus (56800), ganglion impar block (64520), various neurostimulation and spinal cord stimulation codes (e.g., 63650, 63655, 63685, 64561, 64581), biofeedback (90901, 90912/90913), photodynamic therapy (96567, 96573), acupuncture series (97810‑98714), and multiple J‑codes for interferons and botulinum toxin (e.g., J0585).

• Prior authorization/coverage review may be required when these services are proposed.
• Use of CPT/HCPCS codes listed as 'not covered' may trigger claim denial when submitted for the indications in this CPB.

Prior authorization for excisional/surgical treatments

Surgical procedures (local excision, total vestibulectomy, perineoplasty) are described as last‑resort options after failure of conservative management; prior authorization may be required to confirm documented failure of appropriate conservative therapies and localized refractory symptoms before approving surgery.

• Documented failure of appropriate conservative therapies (topical/oral medications, physical therapy, biofeedback, guided nerve blocks) is expected prior to surgery.
• Pain should be localized to the vestibule (e.g., cotton swab testing) and refractory to prior treatments to support excisional surgery.

Consider prior authorization for limited‑evidence interventions (BTX, lasers)

Interventions with limited or preliminary evidence (for example, botulinum toxin injections and laser therapies) are noted as having insufficient evidence and may be subject to prior authorization or payer review before approval.

• Botulinum toxin type A has limited evidence and is often not covered for this indication.
• Laser therapies are described as having low-level evidence and are not recommended for routine practice; payer review may be required.

Prior authorization may be required for LI‑SWT (novel device‑based procedure)

Low‑intensity shockwave therapy (LI‑SWT) is supported only by a single small RCT (n=32); prior authorization may be required with documentation of failed conservative therapy and submission of trial‑level outcomes to justify coverage.

• LI‑SWT evidence limited to a small, single‑center RCT (n=32); document prior conservative therapies and objective outcome measures (VAS, algometer).
• Prior authorization may request trial protocol details and follow‑up outcome measures.

Prior authorization advised for experimental/novel therapies

Treatments described as novel or investigational (e.g., LI‑SWT, Ladylift non‑ablative laser, Meclon Lenex vulvar emulgel) have limited and preliminary evidence; prior authorization is advised and may require submission of the study/procedure protocol, prior standard therapies tried, and relevant outcome measures.

• Submit trial protocol or device details, treatment schedule, and objective baseline/follow‑up pain scores (e.g., VAS) when requesting coverage.
• Document prior use and failure of established noninvasive therapies (pelvic floor PT, multimodal somato‑cognitive therapy).

No explicit prior‑auth codes specified in this bulletin

The policy document does not list explicit prior authorization codes or state formal mandatory prior authorization requirements for these services; individual payer plan rules may still apply.

• No specific prior authorization codes or explicit mandatory prior‑auth triggers are specified in the policy text provided.

Require documented conservative therapy failure before surgery

Surgery (vestibulectomy/perineoplasty) is considered after failure of conservative measures — providers should document that vulvar care, physical therapy, and appropriate pharmacotherapy (including analgesics) were tried and failed prior to proposing surgery.

• Conservative measures (vulvar care, physical therapy, pharmacotherapy including analgesics) must have been tried and failed before vestibulectomy is considered.

Emphasize conservative measures before surgery

Guidelines and expert reviews emphasize trial of conservative measures — topical/oral medications, pelvic floor physical therapy, biofeedback, and guided nerve blocks — before considering surgical intervention.

• Follow multidisciplinary conservative options (topical/oral meds, PT, biofeedback, nerve blocks) prior to invasive interventions.
• Document response and duration of conservative treatments.

Follow stepped care: multidisciplinary first‑line, reserve surgery/second‑line agents

Expert guidance supports a stepped, multidisciplinary care approach and reserves surgery or second‑line agents (e.g., capsaicin, botulinum toxin, interferon) for selected patients after first‑line therapies fail.

• Multidisciplinary care (psychological therapies, pelvic floor PT) is first‑line.
• Second‑line or conditional therapies should be reserved for refractory cases and have limited evidence.

Stepwise preference for non‑pharmacologic interventions and selective surgery

Non‑pharmacological interventions (psychological therapy, pelvic floor physical therapy) are preferred first‑line options, with selective use of surgery for provoked vestibulodynia when indicated.

• Consider psychological interventions and pelvic floor PT before experimental therapies.
• Vestibulectomy supported as an option for provoked vestibulodynia after conservative care fails.

Recommend conservative therapy prior to novel interventions

Before offering novel interventions, consider established noninvasive therapies such as pelvic floor physical therapy and multi‑modal somato‑cognitive therapy; these should be attempted prior to approving experimental treatments.

• Document completion and response to physiotherapy‑based interventions prior to novel device or drug interventions.
• Recommend conservative, evidence‑supported noninvasive therapies before experimental options.

No formal step‑therapy mandates specified

The document does not specify formal step‑therapy program requirements or mandated step edits; it notes recommended sequencing but lists no enforceable step‑therapy rules in these excerpts.

• No explicit payer step‑therapy requirements are specified in the policy text provided.

Document diagnosis and prior conservative therapy failure to support surgical necessity

When proposing surgery, clinical documentation should explicitly support the diagnosis (vulvodynia/vulvar vestibulitis) and record that appropriate conservative measures were tried and failed to justify medical necessity for excisional procedures.

• Include documentation of prior conservative therapies attempted and their outcomes.
• Record examination findings confirming diagnosis and localization of pain.

Document cotton‑swab localization and prior therapy failure

Document localization of painful vestibular areas (e.g., cotton‑swab testing) and note prior failure of conservative therapies; cotton‑swab testing is described as part of preoperative localization and supports excisional surgery decisions.

• Record cotton‑swab test localization and correspondence to planned excision area.
• Include prior treatment history showing lack of adequate response.

Document VAS and cotton‑swab test outcomes for ESWT/LI‑SWT

For ESWT/LI‑SWT outcomes, document baseline and follow‑up VAS pain scores and cotton‑swab test (CST) where used; the ESWT RCT reported >30% pain reductions at 1, 4, and 12 weeks in the treatment group.

• Record VAS and CST scores at baseline and at follow‑up intervals (1, 4, 12 weeks for ESWT).
• Provide objective measures (algometer, CST) where available to support clinical effect.

Document VAS, dyspareunia, vestibular health indices for laser therapies

Laser therapy study reports commonly document VAS pain scores, dyspareunia scores, vestibular health indices, and patient‑reported improvement and satisfaction; include these measures for any coverage request.

• Collect VAS, Marinoff dyspareunia scores, vestibular health index, and patient global impression measures for laser treatments.
• Note that laser study protocols and reporting were heterogeneous.

Document imaging guidance, agents, and pain scores for ganglion impar block

For ganglion impar block, document imaging guidance (CT vs fluoroscopy), approach, agents administered, pre‑ and post‑procedure pain scores, and number/timing of infiltrations to support the claim.

• Specify imaging modality used and needle approach.
• Report VAS before, immediately after, and at follow‑up (e.g., Day 15) and the number of infiltrations.

Required clinical documentation elements for novel/experimental therapies

Clinical documentation supporting investigational or novel interventions should include baseline and follow‑up pain scores (e.g., VAS), objective measures used in studies (algometer, CST, FSFI), and detailed treatment protocol elements (device, waveform, medication concentration, session frequency) and follow‑up duration.

• Provide objective outcome measures (algometer readings, FSFI, Wong‑Baker) and VAS at specified intervals.
• Include full treatment protocol details (device model, energy settings, number/frequency of sessions) and duration of follow‑up.

Denial risk for claims based solely on small preliminary studies

Claims submitted for interventions supported only by small, preliminary studies (small sample sizes, short follow‑up) may be at risk for denial if higher‑level evidence or longer‑term data are required by the payer.

• Evidence described as preliminary (small n and limited follow‑up) increases risk of coverage denial if stronger evidence is requested.
• Consider including more robust outcome data and longer follow‑up when requesting coverage.

Potential denial risk when submitting listed not‑covered CPT/HCPCS codes

Use of CPT/HCPCS codes enumerated as 'not covered' in this bulletin (examples: 0101T, 56800, 63650, 63655, 63685, 64520, 64550, 64561, 64581, 64614, 64630, 64646‑64647, 90867‑90869, 90880, 90901, 90912‑90913, 96567, 96573, 97810‑98714) may trigger claim denial when submitted for the indications listed in this CPB.

• Confirm coding and medical necessity prior to submission; these codes are listed as not covered for the CPB indications.
• Prior authorization or exception process may be required if locally permitted.

Denial risk: vestibuloplasty ineffective

Vestibuloplasty (denervation without excision) has been shown to be ineffective and procedures with known poor outcomes may be denied as not medically necessary.

• Avoid proposing vestibuloplasty as it is reported to be ineffective.
• Expect denials for procedures with demonstrated poor outcomes.

Coverage limitation: botulinum toxin often not covered for vulvodynia

Insurance coverage for botulinum toxin type A for vulvodynia is typically limited and often not covered when used for this indication; providers should anticipate coverage restrictions or denials.

• Botulinum toxin is described as expensive and typically not covered for vulvodynia.
• Provide strong supporting documentation and rationale if requesting coverage.

Denial risk: laser not routinely recommended for vulvodynia

Laser therapies for vulvodynia or lichen sclerosus are not recommended for routine clinical practice outside well‑designed clinical trials or special governance arrangements; expect payer scrutiny and potential denial for routine use.

• Laser should be limited to clinical trials or special governance settings per best‑practice guidance.
• Routine clinical claims for laser therapies may be reviewed and potentially denied.

Denial risk from laser evidence limitations and protocol heterogeneity

Heterogeneous and poorly reported laser protocols with limited follow‑up make effectiveness uncertain; lack of standardized protocols may lead to requests for additional evidence or coverage denial.

• Provide standardized protocol details and longer‑term follow‑up when seeking coverage for laser therapies.
• Heterogeneous parameters and reporting increase likelihood of documentation requests or denial.

Denial risk for therapies supported only by small, short‑term studies

Because many studies cited are small and short‑term, claims for therapies supported only by these preliminary data may be at risk for denial if payers require higher‑level evidence or longer follow‑up.

• Small sample sizes and limited observation periods increase risk of denial for investigational therapies.
• Include larger trial data or extended follow‑up where available to reduce denial risk.